BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ma Z, Cao Q, Xiong Y, Zhang E, Lu M. Interaction between Hepatitis B Virus and Toll-Like Receptors: Current Status and Potential Therapeutic Use for Chronic Hepatitis B. Vaccines (Basel) 2018;6:E6. [PMID: 29337856 DOI: 10.3390/vaccines6010006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Megahed FAK, Zhou X, Sun P. The Interactions between HBV and the Innate Immunity of Hepatocytes. Viruses 2020;12:E285. [PMID: 32151000 DOI: 10.3390/v12030285] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
2 Kayesh MEH, Kohara M, Tsukiyama-Kohara K. Toll-Like Receptor Response to Hepatitis B Virus Infection and Potential of TLR Agonists as Immunomodulators for Treating Chronic Hepatitis B: An Overview. Int J Mol Sci 2021;22:10462. [PMID: 34638802 DOI: 10.3390/ijms221910462] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Chang S, Wang LH, Chen BS. Investigating Core Signaling Pathways of Hepatitis B Virus Pathogenesis for Biomarkers Identification and Drug Discovery via Systems Biology and Deep Learning Method. Biomedicines. 2020;8. [PMID: 32878239 DOI: 10.3390/biomedicines8090320] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Prifti GM, Moianos D, Giannakopoulou E, Pardali V, Tavis JE, Zoidis G. Recent Advances in Hepatitis B Treatment. Pharmaceuticals (Basel) 2021;14:417. [PMID: 34062711 DOI: 10.3390/ph14050417] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Aslam MS, Zaidi SZJ, Toor RH, Gull I, Iqbal MM, Abbas Z, Tipu I, Ahmed A, Athar MA, Harito C, Hassan SU. Interferon α2-Thymosin α1 Fusion Protein (IFNα2-Tα1): A Genetically Engineered Fusion Protein with Enhanced Anticancer and Antiviral Effect. Materials (Basel) 2021;14:3318. [PMID: 34203928 DOI: 10.3390/ma14123318] [Reference Citation Analysis]
6 Ayithan N, Ghosh A, Dwivedi A, Wallin JJ, Tan SK, Chen D, Kottilil S, Poonia B. Oral Selective TLR8 Agonist Selgantolimod Induces Multiple Immune Cell Responses in Humans. Viruses 2021;13:2400. [PMID: 34960669 DOI: 10.3390/v13122400] [Reference Citation Analysis]
7 You H, Qin S, Zhang F, Hu W, Li X, Liu D, Kong F, Pan X, Zheng K, Tang R. Regulation of Pattern-Recognition Receptor Signaling by HBX During Hepatitis B Virus Infection. Front Immunol 2022;13:829923. [PMID: 35251017 DOI: 10.3389/fimmu.2022.829923] [Reference Citation Analysis]
8 Zeng Y, Wu W, Fu Y, Chen S, Chen T, Yang B, Ou Q. Toll-like receptors, long non-coding RNA NEAT1, and RIG-I expression are associated with HBeAg-positive chronic hepatitis B patients in the active phase. J Clin Lab Anal 2019;33:e22886. [PMID: 30924966 DOI: 10.1002/jcla.22886] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
9 Zhao H, Han Q, Yang A, Wang Y, Wang G, Lin A, Wang X, Yin C, Zhang J. CpG-C ODN M362 as an immunoadjuvant for HBV therapeutic vaccine reverses the systemic tolerance against HBV. Int J Biol Sci 2022;18:154-65. [PMID: 34975324 DOI: 10.7150/ijbs.62424] [Reference Citation Analysis]
10 Bartoli A, Gabrielli F, Tassi A, Cursaro C, Pinelli A, Andreone P. Treatments for HBV: A Glimpse into the Future. Viruses 2021;13:1767. [PMID: 34578347 DOI: 10.3390/v13091767] [Reference Citation Analysis]
11 Wu T, Li F, Chen Y, Wei H, Tian Z, Sun C, Sun R. CD4+ T Cells Play a Critical Role in Microbiota-Maintained Anti-HBV Immunity in a Mouse Model. Front Immunol. 2019;10:927. [PMID: 31114580 DOI: 10.3389/fimmu.2019.00927] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
12 Lee HW, Lee JS, Ahn SH. Hepatitis B Virus Cure: Targets and Future Therapies. Int J Mol Sci 2020;22:E213. [PMID: 33379331 DOI: 10.3390/ijms22010213] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
13 Magri A, Harris JM, D’arienzo V, Minisini R, Jühling F, Wing PAC, Rapetti R, Leutner M, Testoni B, Baumert TF, Zoulim F, Balfe P, Pirisi M, Mckeating JA. Inflammatory Gene Expression Associates with Hepatitis B Virus cccDNA- but Not Integrant-Derived Transcripts in HBeAg Negative Disease. Viruses 2022;14:1070. [DOI: 10.3390/v14051070] [Reference Citation Analysis]
14 Federico S, Pozzetti L, Papa A, Carullo G, Gemma S, Butini S, Campiani G, Relitti N. Modulation of the Innate Immune Response by Targeting Toll-like Receptors: A Perspective on Their Agonists and Antagonists. J Med Chem 2020;63:13466-513. [PMID: 32845153 DOI: 10.1021/acs.jmedchem.0c01049] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
15 Wang X, Zhu J, Zhang Y, Li Y, Ma T, Li Q, Xu J, Xu L. The doses of plasmid backbone plays a major role in determining the HBV clearance in hydrodynamic injection mouse model. Virol J 2018;15:89. [PMID: 29783985 DOI: 10.1186/s12985-018-1002-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
16 Akbar SMF, Al Mahtab M, Yoshida O, Hiasa Y. Cellular and Molecular Mechanisms Underlying Scope and Limitation of Ongoing and Innovative Therapies for Treating Chronic Hepatitis B. Livers 2022;2:1-14. [DOI: 10.3390/livers2010001] [Reference Citation Analysis]
17 Akbar SMF, Al Mahtab M, Khan S, Yoshida O, Aguilar JC, Gerardo GN, Hiasa Y. Innovative Therapies Targeting the Virus and the Host for Treating Chronic Hepatitis B Virus Infection: From Bench to Bedside. Vaccines 2022;10:746. [DOI: 10.3390/vaccines10050746] [Reference Citation Analysis]
18 Nahand JS, Karimzadeh MR, Nezamnia M, Fatemipour M, Khatami A, Jamshidi S, Moghoofei M, Taghizadieh M, Hajighadimi S, Shafiee A, Sadeghian M, Bokharaei-Salim F, Mirzaei H. The role of miR-146a in viral infection. IUBMB Life 2020;72:343-60. [PMID: 31889417 DOI: 10.1002/iub.2222] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
19 Zhang Z, Wang C, Liu Z, Zou G, Li J, Lu M. Host Genetic Determinants of Hepatitis B Virus Infection. Front Genet. 2019;10:696. [PMID: 31475028 DOI: 10.3389/fgene.2019.00696] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
20 Wang Q, Zhang H, Chen Z, Chen L, Pan F, Zhou Q. Proliferation of CD11b+ myeloid cells induced by TLR4 signaling promotes hepatitis B virus clearance. Cytokine 2022;153:155867. [PMID: 35390759 DOI: 10.1016/j.cyto.2022.155867] [Reference Citation Analysis]
21 Campos-Valdez M, Monroy-Ramírez HC, Armendáriz-Borunda J, Sánchez-Orozco LV. Molecular Mechanisms during Hepatitis B Infection and the Effects of the Virus Variability. Viruses 2021;13:1167. [PMID: 34207116 DOI: 10.3390/v13061167] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Gane E, Pastagia M, Schwertschlag U, De Creus A, Schwabe C, Vandenbossche J, Slaets L, Fevery B, Smyej I, Wu LS, Li R, Siddiqui S, Oey A, Musto C, Van Remoortere P. Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JNJ-64794964, a TLR-7 agonist, in healthy adults. Antiviral Therapy 2021;26:58-68. [DOI: 10.1177/13596535211056581] [Reference Citation Analysis]
23 Sandmann L, Cornberg M. Towards eradication of HBV: Treatment approaches and status of clinical trials. Curr Opin Pharmacol 2021;60:232-40. [PMID: 34474210 DOI: 10.1016/j.coph.2021.07.008] [Reference Citation Analysis]
24 Michalak TI. Diverse Virus and Host-Dependent Mechanisms Influence the Systemic and Intrahepatic Immune Responses in the Woodchuck Model of Hepatitis B. Front Immunol. 2020;11:853. [PMID: 32536912 DOI: 10.3389/fimmu.2020.00853] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
25 Yan Y, Zhao W, Liu W, Li Y, Wang X, Xun J, Davgadorj C. CCL19 enhances CD8+ T-cell responses and accelerates HBV clearance. J Gastroenterol 2021;56:769-85. [PMID: 34218330 DOI: 10.1007/s00535-021-01799-8] [Reference Citation Analysis]
26 Lee AR, Park YK, Dezhbord M, Kim K. Interaction between the Hepatitis B Virus and Cellular FLIP Variants in Viral Replication and the Innate Immune System. Viruses 2022;14:373. [DOI: 10.3390/v14020373] [Reference Citation Analysis]
27 Neag MA, Mitre AO, Catinean A, Buzoianu AD. Overview of the microbiota in the gut-liver axis in viral B and C hepatitis. World J Gastroenterol 2021; 27(43): 7446-7461 [PMID: 34887642 DOI: 10.3748/wjg.v27.i43.7446] [Reference Citation Analysis]
28 Borkakoty B, Sarmah MD, Majumdar T, Bhattacharjee CK, Baruah PJ, Biswas D, Kaur H. Role of Innate Immune Regulatory Genes, FOXP3 and FOS in Chronic Hepatitis B Infection. Viral Immunol 2022;35:338-44. [PMID: 35580072 DOI: 10.1089/vim.2021.0145] [Reference Citation Analysis]
29 Khanam A, Chua JV, Kottilil S. Immunopathology of Chronic Hepatitis B Infection: Role of Innate and Adaptive Immune Response in Disease Progression. Int J Mol Sci 2021;22:5497. [PMID: 34071064 DOI: 10.3390/ijms22115497] [Reference Citation Analysis]
30 Kayesh MEH, Hashem MA, Kitab B, Tsukiyama-Kohara K. Pathogenesis and Immune Response Caused by Vector-Borne and Other Viral Infections in a Tupaia Model. Microorganisms 2019;7:E686. [PMID: 31842286 DOI: 10.3390/microorganisms7120686] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
31 Lan T, Wei Z, He Y, Wan S, Liu L, Cheng B, Li R, Chen H, Liu G, Meng Z. Immunostimulatory siRNA with a uridine bulge leads to potent inhibition of HBV and activation of innate immunity. Virol J 2021;18:37. [PMID: 33602251 DOI: 10.1186/s12985-021-01509-z] [Reference Citation Analysis]
32 Meng Z, Chen Y, Lu M. Advances in Targeting the Innate and Adaptive Immune Systems to Cure Chronic Hepatitis B Virus Infection. Front Immunol 2019;10:3127. [PMID: 32117201 DOI: 10.3389/fimmu.2019.03127] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 10.5] [Reference Citation Analysis]
33 Nasir M, Wu GY. Prevention of HBV Recurrence after Liver Transplant: A Review. J Clin Transl Hepatol 2020;8:150-60. [PMID: 32832395 DOI: 10.14218/JCTH.2020.00003] [Reference Citation Analysis]
34 Ligat G, Goto K, Verrier E, Baumert TF. Targeting Viral cccDNA for Cure of Chronic Hepatitis B. Curr Hepatology Rep 2020;19:235-44. [DOI: 10.1007/s11901-020-00534-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
35 Zhang E, Ma Z, Li Q, Yan H, Liu J, Wu W, Guo J, Zhang X, Kirschning CJ, Xu H, Lang PA, Yang D, Dittmer U, Yan H, Lu M. TLR2 Stimulation Increases Cellular Metabolism in CD8+ T Cells and Thereby Enhances CD8+ T Cell Activation, Function, and Antiviral Activity. J Immunol 2019;203:2872-86. [PMID: 31636238 DOI: 10.4049/jimmunol.1900065] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
36 Ligat G, Verrier ER, Nassal M, Baumert TF. Hepatitis B virus-host interactions and novel targets for viral cure. Curr Opin Virol 2021;49:41-51. [PMID: 34029994 DOI: 10.1016/j.coviro.2021.04.009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Yadav S, Verma V, Singh Dhanda R, Yadav M. Insights into the toll-like receptors in sexually transmitted infections. Scand J Immunol 2021;93:e12954. [PMID: 32762084 DOI: 10.1111/sji.12954] [Reference Citation Analysis]